You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Remitting

Showing 1 - 25 of 1,020
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsing Remitting Multiple Sclerosis Trial (PIPE-307 Dose A, PIPE-307 Dose B, Placebo)

Not yet recruiting
  • Relapsing Remitting Multiple Sclerosis
  • PIPE-307 Dose A
  • +2 more
  • (no location specified)
Oct 9, 2023

Relapsing-remitting Multiple Sclerosis Trial (CT-P53, US-Ocrevus, EU-Ocrevus)

Not yet recruiting
  • Relapsing-remitting Multiple Sclerosis
  • CT-P53
  • +2 more
  • (no location specified)
Jun 7, 2023

Assess New Participant's Perspectives Beyond Clinical Efficacy

Not yet recruiting
  • Multiple Sclerosis, Relapsing-Remitting
    • (no location specified)
    Nov 7, 2023

    Multiple Sclerosis Trial in Montpellier (Magnetic Resonance Imaging, Blood withdrawal, Neuropsychological tests)

    Not yet recruiting
    • Multiple Sclerosis
    • Magnetic Resonance Imaging
    • +2 more
    • Montpellier, France
      Neurology Department, Hopital Gui de Chauliac
    Jul 18, 2023

    Multiple Sclerosis, Relapsing-Remitting Trial in Elazig (Reiki)

    Recruiting
    • Multiple Sclerosis, Relapsing-Remitting
    • Reiki
    • Elazıg, Turkey
      Firat University
    Nov 8, 2023

    Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

    Not yet recruiting
    • Relapsing-remitting Multiple Sclerosis (RRMS)
      • (no location specified)
      Apr 11, 2023

      Multiple Sclerosis Trial in Genova (7-day Fasting-Mimicking Diet (7-DAY FMD))

      Active, not recruiting
      • Multiple Sclerosis
      • 7-day Fasting-Mimicking Diet (7-DAY FMD)
      • Genova, Italy
        Ospedale San Martino
      Sep 8, 2023

      Describe Switching FromFirst- or Second-line Disease Modifying

      Not yet recruiting
      • Multiple Sclerosis, Relapsing-Remitting
        • (no location specified)
        Dec 12, 2022

        Multiple Sclerosis, Relapsing-Remitting Trial in Munich, Mainz, Münster (Vivomixx®, Conjugated linoleic acid (CLA/Tonalin® FFA

        Not yet recruiting
        • Multiple Sclerosis, Relapsing-Remitting
        • Vivomixx®
        • +3 more
        • Munich, Bavaria, Germany
        • +2 more
        Jun 15, 2023

        Multiple Sclerosis, Relapsing-Remitting, Fatigue Trial (TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY], Placebo)

        Withdrawn
        • Multiple Sclerosis, Relapsing-Remitting
        • Fatigue
        • TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]
        • Placebo
        • Boston, Massachusetts
          Massachusetts General Hospital
        Nov 14, 2022

        Bafiertam Treatment In Routine Clinical Practice

        Enrolling by invitation
        • Relapsing Remitting Multiple Sclerosis
        • Monomethyl Fumarate
        • West Hollywood, California
        • +1 more
        Aug 3, 2023

        Multiple Sclerosis, Relapsing-Remitting Trial in La Jolla (Autologous hematopoietic stem cell transplantation,

        Recruiting
        • Multiple Sclerosis, Relapsing-Remitting
        • Autologous hematopoietic stem cell transplantation
        • +2 more
        • La Jolla, California
          Scripps Green Hospital
        Aug 16, 2022

        Deficient T Regulatory Cell Function in Relapsing Remitting

        Recruiting
        • Relapse Remitting Multiple Sclerosis
          • Philadelphia, Pennsylvania
            Thomas Jefferson University
          Jun 13, 2022

          Lesion Load and Location in Relation to Cognition, Fatigue and

          Completed
          • Relapsing Remitting Multiple Sclerosis
          • VolBrain, a fully automated platform to generate the volumetric data (lesion count, volume and location as well as different atrophy measures)
          • Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
          • Assiut, Egypt
            Eman Khedr
          Oct 27, 2022

          Multiple Sclerosis, Relapsing-Remitting Trial in Porto Alegre (Cladribine 10 mg oral tablet)

          Active, not recruiting
          • Multiple Sclerosis, Relapsing-Remitting
          • Cladribine 10 mg oral tablet
          • Porto Alegre, RS, Brazil
            Pontifical Catholic University of Rio Grande do Sul
          Jun 5, 2023

          Generic Fingolimod in Relapsing-Remitting Multiple Sclerosis in

          Recruiting
          • Relapsing-Remitting Multiple Sclerosis
          • Alexandria, Egypt
          • +1 more
          Jun 14, 2022

          A Post-Authorization, Long-term Study of Ozanimod Real-world

          Active, not recruiting
          • Multiple Sclerosis, Relapsing-Remitting
            • Bethesda, Maryland
              Evidera
            Oct 31, 2022

            Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI

            Recruiting
            • Multiple Sclerosis, Relapsing-Remitting
            • West Orange, New Jersey
              Kessler Foundation
            Oct 12, 2022

            Cardiometabolic Health in Multiple Sclerosis

            Recruiting
            • Multiple Sclerosis, Relapsing-Remitting
              • Diepenbeek, Limburg, Belgium
                Hasselt University
              Mar 1, 2023

              Multiple Sclerosis (MS) Patients

              Not yet recruiting
              • Multiple Sclerosis, Relapsing-Remitting
              • +2 more
                • (no location specified)
                Dec 15, 2022

                Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive Trial in Tokyo (OCH-NCNP1, Placebo)

                Active, not recruiting
                • Multiple Sclerosis, Relapsing-Remitting
                • Multiple Sclerosis, Secondary Progressive
                • Tokyo, Japan
                  National Center of Neurology and Psychiatry
                Sep 28, 2022

                Multiple Sclerosis, Relapsing-Remitting Trial in Paris (50 ml blodd sampling)

                Not yet recruiting
                • Multiple Sclerosis, Relapsing-Remitting
                • 50 ml blodd sampling
                • Paris, France
                  Hôpital La Pitié - Salpêtrière
                Aug 16, 2022

                Relapsing Remitting Multiple Sclerosis Trial in Glasgow (Clinical assessment)

                Enrolling by invitation
                • Relapsing Remitting Multiple Sclerosis
                • Clinical assessment
                • Glasgow, United Kingdom
                  Clinical Research Facility
                Jul 20, 2022

                Multiple Sclerosis, Relapsing-Remitting Trial in Amsterdam (Ocrelizumab)

                Recruiting
                • Multiple Sclerosis, Relapsing-Remitting
                • Amsterdam, Noord-Holland, Netherlands
                  Amsterdam UMC, location VU
                Apr 21, 2022

                Multiple Sclerosis, Relapsing-Remitting Trial in Switzerland (serum Neurofilament Filament Light chain (sNfL) monitoring)

                Not yet recruiting
                • Multiple Sclerosis, Relapsing-Remitting
                • serum Neurofilament Filament Light chain (sNfL) monitoring
                • Basel, Basel Stadt, Switzerland
                • +7 more
                Oct 17, 2023